Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636503 · ClinicalTrials.gov registry record · Phase 1
Rituximab + Immunotherapy in Follicular Lymphoma
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03636503 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 24 participants.
The verdict
NCT03636503, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma. The drugs involved are: * Rituximab * Utomilumab * Avelumab * PF-04518600
Interventions
- DRUG Rituximab
- DRUG Avelumab
- DRUG Utomilumab
- DRUG PF04518600
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2023-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03636503
The ClinicalTrials.gov registry entry for NCT03636503 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rituximab is the first listed.
NCT03636503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03636503 about?
NCT03636503 is a clinical study titled "Rituximab + Immunotherapy in Follicular Lymphoma". This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma. The drugs involved are: * Rituximab * Utomilumab * Avelumab * PF-04518600
What is the current status of trial NCT03636503?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-10-30. Estimated completion is 2023-07-30.
What interventions are being tested in trial NCT03636503?
The interventions under investigation include: Rituximab (DRUG), Avelumab (DRUG), Utomilumab (DRUG), PF04518600 (DRUG).
Who is sponsoring clinical trial NCT03636503?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.